表紙
市場調査レポート

血液腫瘍 - パイプライン製品の分析

Hematological Tumor - Pipeline Review, H1 2014

発行 Global Markets Direct 商品コード 257810
出版日 ページ情報 英文 450 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
血液腫瘍 - パイプライン製品の分析 Hematological Tumor - Pipeline Review, H1 2014
出版日: 2014年06月30日 ページ情報: 英文 450 Pages
概要

血液腫瘍は、血液、骨髄、リンパ節に影響する癌の一種であり、骨髄系細胞由来またはリンパ細胞株由来の場合があります。異常な出血、感染症への罹患、疲労感、息切れ、骨痛、リンパ腺の腫れ、体重減少および夜間の発汗などの症状があり、手術、化学療法、放射線治療などが治療法として挙げられます。

当レポートでは、血液腫瘍に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

血液腫瘍の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca PLC
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • MedImmune, LLC
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • AbGenomics International, Inc.
  • Dainippon Sumitomo Pharma Co., Ltd.
  • Gamida Cell Ltd.
  • Infinity Pharmaceuticals, Inc.
  • Symphogen A/S
  • Piramal Enterprises Limited
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Eisai Co., Ltd.
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Astex Pharmaceuticals, Inc.
  • Taiho Pharmaceutical Co., Ltd.
  • Celgene Corporation
  • Onyx Pharmaceuticals, Inc.
  • Bayer AG
  • Incyte Corporation
  • 4SC AG
  • Basilea Pharmaceutica AG
  • Compugen Ltd.
  • Patrys Limited
  • Curis, Inc.
  • Portola Pharmaceuticals, Inc.
  • Pharmacyclics, Inc.
  • BioInvent International AB
  • Xenetic Biosciences plc
  • Threshold Pharmaceuticals, Inc.
  • CrystalGenomics, Inc.
  • Rexahn Pharmaceuticals, Inc.
  • Nerviano Medical Sciences
  • Erytech Pharma SA
  • Aegera Therapeutics Inc.
  • Altor BioScience Corporation
  • Aileron Therapeutics, Inc.
  • Agios Pharmaceuticals, Inc.
  • Arno Therapeutics, Inc.
  • OncoMed Pharmaceuticals, Inc.
  • Constellation Pharmaceuticals, Inc.
  • Bluebird bio, Inc.
  • Stemline Therapeutics, Inc.
  • AndroScience Corporation
  • Fate Therapeutics, Inc.
  • Esperance Pharmaceuticals, Inc.
  • BIND Therapeutics, Inc.
  • Tragara Pharmaceuticals, Inc.
  • Pharma Mar, S.A.
  • AmpliMed Corporation
  • Aprea AB
  • arGEN-X BV
  • TRACON Pharmaceuticals, Inc.
  • Merus B.V.
  • Vaxiion Therapeutics, Inc.
  • IkerChem S.L.
  • Immunovative Therapies, Ltd.
  • Targazyme, Inc.
  • Igenica, Inc.
  • Selvita S.A
  • Karyopharm Therapeutics, Inc.
  • Eddingpharm
  • OncoEthix SA
  • Jasco Pharmaceuticals, LLC.
  • Rhizen Pharmaceuticals SA
  • ADC Therapeutics Sarl
  • Ability Pharma, SL
  • Pharmedartis GmbH
  • Oncology Venture ApS

治療薬の評価

  • 単独療法の製品
  • 併用療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • StemEx
  • alisertib
  • panobinostat
  • crizotinib
  • oprozomib
  • idelalisib
  • SL-401
  • CG-200745
  • APO-010
  • Oncohist
  • MEDI-551
  • erismodegib
  • danusertib
  • afuresertib
  • gandotinib
  • encorafenib
  • FT-1050
  • HSC-835
  • abexinostat hydrochloride
  • AT-9283
  • AR-42
  • ruxolitinib phosphate
  • NiCord
  • APR-246
  • AlloStim
  • tisagenlecleucel-T
  • ALT-803
  • PRT-2070
  • CC-115
  • Natural Killer Cell Product for Adoptive Cell-Mediated Therapy
  • ARGX-110
  • GSK-525762
  • E-7438
  • pevonedistat hydrochloride
  • 4SC-202
  • carfilzomib
  • TG-02
  • TH-302
  • MLN-0128
  • P-1446
  • lurbinectedin
  • SNX-5422
  • NMS-1116354
  • nivolumab
  • glasdegib
  • duvelisib
  • AZD-9150
  • pembrolizumab
  • PRI-724
  • TRC-102
  • ARGX-111
  • LGH-447
  • RG-7446
  • AG-221
  • AZD-1208
  • FT-1050
  • RG-7388
  • P-2745
  • WT-2725
  • OTX-015
  • KPT-330
  • OMP-52M51
  • CB-839
  • RP-6530
  • KPT-227
  • KPT-205
  • KPT-127
  • KPT-185
  • UCB + HPDSC
  • TAK-659
  • HDM-201
  • PAT-LM1
  • asparaginase
  • SL-201
  • ASC-ST.Z1
  • IKH-02
  • ACTB-1010
  • AlloVax
  • CU-201
  • EP-400
  • PAT-SM3
  • PAT-SM5
  • ABTL-1014
  • ASC-ST.X1
  • Monoclonal Antibody Drug Conjugates to Inhibit DNA Synthesis for Solid and Hematological Tumors
  • ATSP-7041
  • RX-0201N
  • Small Molecule to Inhibit Pim Kinase for Oncology
  • Small Molecules To Inhibit BET For Cancer
  • Small Molecules to Inhibit BTK Kinase for Immunology and Oncology
  • TAS-116
  • PAT-NM3
  • CLL-05
  • BC-2059
  • Small Molecules to Inhibit Pan-PIM Kinase for Cancer
  • BI-1206
  • AMP-423
  • Monoclonal Antibody for Hematological Tumors
  • Chimeric Antigen Receptor (CAR) T Cell for Oncology
  • PMA-406
  • ASC-102
  • IPI-443
  • Small Molecules to Inhibit Kinases for Cancer
  • VM-101
  • Hematologic Tumor Accurin
  • HCI-1684
  • AbGn-122
  • LGB-321
  • Cell Therapy 2 for Cancer
  • Cell Therapy 3 for Cancer
  • Cell Therapy 4 for Cancer
  • Small Molecules to Inhibit DNMT for Solid Tumor and Hematological Tumor
  • Small Molecules to Inhibit JMJ for Solid Tumor and Hematological Tumor
  • Small Molecules to Inhibit AXL Kinase for Hematological Tumor
  • Small Molecules to Inhibit Proteasome for Solid Tumor and Hematological Tumor
  • Monoclonal Antibody Targeting CGEN-15001T for Cancer
  • Small Molecules for Hematological and Solid Cancers
  • Small Molecule to Inhibit Hedgehog for Cancer
  • APR-246 Analogues
  • Small Molecule to Inhibit BTK for Cancer
  • Small Molecule to Inhibit Casein Kinase 1 for Cancer
  • Small Molecules to Inhibit HDAC-2 for Oncology And Central Nervous System Disorders
  • Ubiquitin Proteasome System Inhibitors
  • Drugs to Inhibit Integrin Beta1 For Hematological Tumors
  • Perk Kinase Inhibitor
  • Sym-012
  • Thorium-Anti CD22 Monoclonal Antibody
  • Small Molecule for Hematologic Malignancies
  • Monoclonal Antibodies for Blood Cancers
  • SEL-201
  • SEL-300
  • Small Molecules to Inhibit Kinase for Cancer
  • Drugs to Inhibit DNA Methyl Transferase for Hematological Cancers

パイプライン製品の最新動向

休止中のプロジェクト

開発中止になった製品

製品開発のマイルストーン

  • 注目情報とプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC5071IDB

Summary

Global Markets Direct's, 'Hematological Tumor - Pipeline Review, H1 2014', provides an overview of the Hematological Tumor's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hematological Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hematological Tumor and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hematological Tumor
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hematological Tumor and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hematological Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hematological Tumor pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hematological Tumor
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hematological Tumor pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hematological Tumor Overview
  • Therapeutics Development
    • Pipeline Products for Hematological Tumor - Overview
    • Pipeline Products for Hematological Tumor - Comparative Analysis
  • Hematological Tumor - Therapeutics under Development by Companies
  • Hematological Tumor - Therapeutics under Investigation by Universities/Institutes
  • Hematological Tumor - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Hematological Tumor - Products under Development by Companies
  • Hematological Tumor - Products under Investigation by Universities/Institutes
  • Hematological Tumor - Companies Involved in Therapeutics Development
    • F. Hoffmann-La Roche Ltd.
    • AstraZeneca PLC
    • Eli Lilly and Company
    • GlaxoSmithKline plc
    • MedImmune, LLC
    • Gilead Sciences, Inc.
    • Merck & Co., Inc.
    • AbGenomics International, Inc.
    • Dainippon Sumitomo Pharma Co., Ltd.
    • Gamida Cell Ltd.
    • Infinity Pharmaceuticals, Inc.
    • Symphogen A/S
    • Piramal Enterprises Limited
    • Millennium Pharmaceuticals, Inc.
    • Novartis AG
    • Eisai Co., Ltd.
    • Ono Pharmaceutical Co., Ltd.
    • Pfizer Inc.
    • Astex Pharmaceuticals, Inc.
    • Taiho Pharmaceutical Co., Ltd.
    • Celgene Corporation
    • Onyx Pharmaceuticals, Inc.
    • Bayer AG
    • Incyte Corporation
    • 4SC AG
    • Basilea Pharmaceutica AG
    • Compugen Ltd.
    • Patrys Limited
    • Curis, Inc.
    • Portola Pharmaceuticals, Inc.
    • Pharmacyclics, Inc.
    • BioInvent International AB
    • Xenetic Biosciences plc
    • Threshold Pharmaceuticals, Inc.
    • CrystalGenomics, Inc.
    • Rexahn Pharmaceuticals, Inc.
    • Nerviano Medical Sciences
    • Erytech Pharma SA
    • Aegera Therapeutics Inc.
    • Altor BioScience Corporation
    • Aileron Therapeutics, Inc.
    • Agios Pharmaceuticals, Inc.
    • Arno Therapeutics, Inc.
    • OncoMed Pharmaceuticals, Inc.
    • Constellation Pharmaceuticals, Inc.
    • Bluebird bio, Inc.
    • Stemline Therapeutics, Inc.
    • AndroScience Corporation
    • Fate Therapeutics, Inc.
    • Esperance Pharmaceuticals, Inc.
    • BIND Therapeutics, Inc.
    • Tragara Pharmaceuticals, Inc.
    • Pharma Mar, S.A.
    • AmpliMed Corporation
    • Aprea AB
    • arGEN-X BV
    • TRACON Pharmaceuticals, Inc.
    • Merus B.V.
    • Vaxiion Therapeutics, Inc.
    • IkerChem S.L.
    • Immunovative Therapies, Ltd.
    • Targazyme, Inc.
    • Igenica, Inc.
    • Selvita S.A
    • Karyopharm Therapeutics, Inc.
    • Eddingpharm
    • OncoEthix SA
    • Jasco Pharmaceuticals, LLC.
    • Rhizen Pharmaceuticals SA
    • ADC Therapeutics Sarl
    • Ability Pharma, SL
    • Pharmedartis GmbH
    • Oncology Venture ApS
  • Hematological Tumor - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • StemEx - Drug Profile
    • alisertib - Drug Profile
    • panobinostat - Drug Profile
    • crizotinib - Drug Profile
    • oprozomib - Drug Profile
    • idelalisib - Drug Profile
    • SL-401 - Drug Profile
    • CG-200745 - Drug Profile
    • APO-010 - Drug Profile
    • Oncohist - Drug Profile
    • MEDI-551 - Drug Profile
    • erismodegib - Drug Profile
    • danusertib - Drug Profile
    • afuresertib - Drug Profile
    • gandotinib - Drug Profile
    • encorafenib - Drug Profile
    • FT-1050 - Drug Profile
    • HSC-835 - Drug Profile
    • abexinostat hydrochloride - Drug Profile
    • AT-9283 - Drug Profile
    • AR-42 - Drug Profile
    • ruxolitinib phosphate - Drug Profile
    • NiCord - Drug Profile
    • APR-246 - Drug Profile
    • AlloStim - Drug Profile
    • tisagenlecleucel-T - Drug Profile
    • ALT-803 - Drug Profile
    • PRT-2070 - Drug Profile
    • CC-115 - Drug Profile
    • Natural Killer Cell Product for Adoptive Cell-Mediated Therapy - Drug Profile
    • ARGX-110 - Drug Profile
    • GSK-525762 - Drug Profile
    • E-7438 - Drug Profile
    • pevonedistat hydrochloride - Drug Profile
    • 4SC-202 - Drug Profile
    • carfilzomib - Drug Profile
    • TG-02 - Drug Profile
    • TH-302 - Drug Profile
    • MLN-0128 - Drug Profile
    • P-1446 - Drug Profile
    • lurbinectedin - Drug Profile
    • SNX-5422 - Drug Profile
    • NMS-1116354 - Drug Profile
    • nivolumab - Drug Profile
    • glasdegib - Drug Profile
    • duvelisib - Drug Profile
    • AZD-9150 - Drug Profile
    • pembrolizumab - Drug Profile
    • PRI-724 - Drug Profile
    • TRC-102 - Drug Profile
    • ARGX-111 - Drug Profile
    • LGH-447 - Drug Profile
    • RG-7446 - Drug Profile
    • AG-221 - Drug Profile
    • AZD-1208 - Drug Profile
    • FT-1050 - Drug Profile
    • RG-7388 - Drug Profile
    • P-2745 - Drug Profile
    • WT-2725 - Drug Profile
    • OTX-015 - Drug Profile
    • KPT-330 - Drug Profile
    • OMP-52M51 - Drug Profile
    • CB-839 - Drug Profile
    • RP-6530 - Drug Profile
    • KPT-227 - Drug Profile
    • KPT-205 - Drug Profile
    • KPT-127 - Drug Profile
    • KPT-185 - Drug Profile
    • UCB + HPDSC - Drug Profile
    • TAK-659 - Drug Profile
    • HDM-201 - Drug Profile
    • PAT-LM1 - Drug Profile
    • asparaginase - Drug Profile
    • SL-201 - Drug Profile
    • ASC-ST.Z1 - Drug Profile
    • IKH-02 - Drug Profile
    • ACTB-1010 - Drug Profile
    • AlloVax - Drug Profile
    • CU-201 - Drug Profile
    • EP-400 - Drug Profile
    • PAT-SM3 - Drug Profile
    • PAT-SM5 - Drug Profile
    • ABTL-1014 - Drug Profile
    • ASC-ST.X1 - Drug Profile
    • Monoclonal Antibody Drug Conjugates to Inhibit DNA Synthesis for Solid and Hematological Tumors - Drug Profile
    • ATSP-7041 - Drug Profile
    • RX-0201N - Drug Profile
    • Small Molecule to Inhibit Pim Kinase for Oncology - Drug Profile
    • Small Molecules To Inhibit BET For Cancer - Drug Profile
    • Small Molecules to Inhibit BTK Kinase for Immunology and Oncology - Drug Profile
    • TAS-116 - Drug Profile
    • PAT-NM3 - Drug Profile
    • CLL-05 - Drug Profile
    • BC-2059 - Drug Profile
    • Small Molecules to Inhibit Pan-PIM Kinase for Cancer - Drug Profile
    • BI-1206 - Drug Profile
    • AMP-423 - Drug Profile
    • Monoclonal Antibody for Hematological Tumors - Drug Profile
    • Chimeric Antigen Receptor (CAR) T Cell for Oncology - Drug Profile
    • PMA-406 - Drug Profile
    • ASC-102 - Drug Profile
    • IPI-443 - Drug Profile
    • Small Molecules to Inhibit Kinases for Cancer - Drug Profile
    • VM-101 - Drug Profile
    • Hematologic Tumor Accurin - Drug Profile
    • HCI-1684 - Drug Profile
    • AbGn-122 - Drug Profile
    • LGB-321 - Drug Profile
    • Cell Therapy 2 for Cancer - Drug Profile
    • Cell Therapy 3 for Cancer - Drug Profile
    • Cell Therapy 4 for Cancer - Drug Profile
    • Small Molecules to Inhibit DNMT for Solid Tumor and Hematological Tumor - Drug Profile
    • Small Molecules to Inhibit JMJ for Solid Tumor and Hematological Tumor - Drug Profile
    • Small Molecules to Inhibit AXL Kinase for Hematological Tumor - Drug Profile
    • Small Molecules to Inhibit Proteasome for Solid Tumor and Hematological Tumor - Drug Profile
    • Monoclonal Antibody Targeting CGEN-15001T for Cancer - Drug Profile
    • Small Molecules for Hematological and Solid Cancers - Drug Profile
    • Small Molecule to Inhibit Hedgehog for Cancer - Drug Profile
    • APR-246 Analogues - Drug Profile
    • Small Molecule to Inhibit BTK for Cancer - Drug Profile
    • Small Molecule to Inhibit Casein Kinase 1 for Cancer - Drug Profile
    • Small Molecules to Inhibit HDAC-2 for Oncology And Central Nervous System Disorders - Drug Profile
    • Ubiquitin Proteasome System Inhibitors - Drug Profile
    • Drugs to Inhibit Integrin Beta1 For Hematological Tumors - Drug Profile
    • Perk Kinase Inhibitor - Drug Profile
    • Sym-012 - Drug Profile
    • Thorium-Anti CD22 Monoclonal Antibody - Drug Profile
    • Small Molecule for Hematologic Malignancies - Drug Profile
    • Monoclonal Antibodies for Blood Cancers - Drug Profile
    • SEL-201 - Drug Profile
    • SEL-300 - Drug Profile
    • Small Molecules to Inhibit Kinase for Cancer - Drug Profile
    • Drugs to Inhibit DNA Methyl Transferase for Hematological Cancers - Drug Profile
  • Hematological Tumor - Recent Pipeline Updates
  • Hematological Tumor - Dormant Projects
  • Hematological Tumor - Discontinued Products
  • Hematological Tumor - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hematological Tumor, H1 2014
  • Number of Products under Development for Hematological Tumor - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Development by Companies, H1 2014 (Contd..1)
  • Number of Products under Development by Companies, H1 2014 (Contd..2)
  • Number of Products under Development by Companies, H1 2014 (Contd..3)
  • Number of Products under Development by Companies, H1 2014 (Contd..4)
  • Number of Products under Development by Companies, H1 2014 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Products under Development by Companies, H1 2014 (Contd..1)
  • Products under Development by Companies, H1 2014 (Contd..2)
  • Products under Development by Companies, H1 2014 (Contd..3)
  • Products under Development by Companies, H1 2014 (Contd..4)
  • Products under Development by Companies, H1 2014 (Contd..5)
  • Products under Development by Companies, H1 2014 (Contd..6)
  • Products under Development by Companies, H1 2014 (Contd..7)
  • Products under Investigation by Universities/Institutes, H1 2014
  • Hematological Tumor - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014
  • Hematological Tumor - Pipeline by AstraZeneca PLC, H1 2014
  • Hematological Tumor - Pipeline by Eli Lilly and Company, H1 2014
  • Hematological Tumor - Pipeline by GlaxoSmithKline plc, H1 2014
  • Hematological Tumor - Pipeline by MedImmune, LLC, H1 2014
  • Hematological Tumor - Pipeline by Gilead Sciences, Inc., H1 2014
  • Hematological Tumor - Pipeline by Merck & Co., Inc., H1 2014
  • Hematological Tumor - Pipeline by AbGenomics International, Inc., H1 2014
  • Hematological Tumor - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014
  • Hematological Tumor - Pipeline by Gamida Cell Ltd., H1 2014
  • Hematological Tumor - Pipeline by Infinity Pharmaceuticals, Inc., H1 2014
  • Hematological Tumor - Pipeline by Symphogen A/S, H1 2014
  • Hematological Tumor - Pipeline by Piramal Enterprises Limited, H1 2014
  • Hematological Tumor - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014
  • Hematological Tumor - Pipeline by Novartis AG, H1 2014
  • Hematological Tumor - Pipeline by Eisai Co., Ltd., H1 2014
  • Hematological Tumor - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014
  • Hematological Tumor - Pipeline by Pfizer Inc., H1 2014
  • Hematological Tumor - Pipeline by Astex Pharmaceuticals, Inc., H1 2014
  • Hematological Tumor - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2014
  • Hematological Tumor - Pipeline by Celgene Corporation, H1 2014
  • Hematological Tumor - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014
  • Hematological Tumor - Pipeline by Bayer AG, H1 2014
  • Hematological Tumor - Pipeline by Incyte Corporation, H1 2014
  • Hematological Tumor - Pipeline by 4SC AG, H1 2014
  • Hematological Tumor - Pipeline by Basilea Pharmaceutica AG, H1 2014
  • Hematological Tumor - Pipeline by Compugen Ltd., H1 2014
  • Hematological Tumor - Pipeline by Patrys Limited, H1 2014
  • Hematological Tumor - Pipeline by Curis, Inc., H1 2014
  • Hematological Tumor - Pipeline by Portola Pharmaceuticals, Inc., H1 2014
  • Hematological Tumor - Pipeline by Pharmacyclics, Inc., H1 2014
  • Hematological Tumor - Pipeline by BioInvent International AB, H1 2014
  • Hematological Tumor - Pipeline by Xenetic Biosciences plc, H1 2014
  • Hematological Tumor - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014
  • Hematological Tumor - Pipeline by CrystalGenomics, Inc., H1 2014
  • Hematological Tumor - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2014
  • Hematological Tumor - Pipeline by Nerviano Medical Sciences, H1 2014
  • Hematological Tumor - Pipeline by Erytech Pharma SA, H1 2014
  • Hematological Tumor - Pipeline by Aegera Therapeutics Inc., H1 2014
  • Hematological Tumor - Pipeline by Altor BioScience Corporation, H1 2014
  • Hematological Tumor - Pipeline by Aileron Therapeutics, Inc., H1 2014
  • Hematological Tumor - Pipeline by Agios Pharmaceuticals, Inc., H1 2014
  • Hematological Tumor - Pipeline by Arno Therapeutics, Inc., H1 2014
  • Hematological Tumor - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2014
  • Hematological Tumor - Pipeline by Constellation Pharmaceuticals, Inc., H1 2014
  • Hematological Tumor - Pipeline by Bluebird bio, Inc., H1 2014
  • Hematological Tumor - Pipeline by Stemline Therapeutics, Inc., H1 2014
  • Hematological Tumor - Pipeline by AndroScience Corporation, H1 2014
  • Hematological Tumor - Pipeline by Fate Therapeutics, Inc., H1 2014
  • Hematological Tumor - Pipeline by Esperance Pharmaceuticals, Inc., H1 2014
  • Hematological Tumor - Pipeline by BIND Therapeutics, Inc., H1 2014
  • Hematological Tumor - Pipeline by Tragara Pharmaceuticals, Inc., H1 2014
  • Hematological Tumor - Pipeline by Pharma Mar, S.A., H1 2014
  • Hematological Tumor - Pipeline by AmpliMed Corporation, H1 2014
  • Hematological Tumor - Pipeline by Aprea AB, H1 2014
  • Hematological Tumor - Pipeline by arGEN-X BV, H1 2014
  • Hematological Tumor - Pipeline by TRACON Pharmaceuticals, Inc., H1 2014
  • Hematological Tumor - Pipeline by Merus B.V., H1 2014
  • Hematological Tumor - Pipeline by Vaxiion Therapeutics, Inc., H1 2014
  • Hematological Tumor - Pipeline by IkerChem S.L., H1 2014
  • Hematological Tumor - Pipeline by Immunovative Therapies, Ltd., H1 2014
  • Hematological Tumor - Pipeline by Targazyme, Inc., H1 2014
  • Hematological Tumor - Pipeline by Igenica, Inc., H1 2014
  • Hematological Tumor - Pipeline by Selvita S.A, H1 2014
  • Hematological Tumor - Pipeline by Karyopharm Therapeutics, Inc., H1 2014
  • Hematological Tumor - Pipeline by Eddingpharm, H1 2014
  • Hematological Tumor - Pipeline by OncoEthix SA, H1 2014
  • Hematological Tumor - Pipeline by Jasco Pharmaceuticals, LLC., H1 2014
  • Hematological Tumor - Pipeline by Rhizen Pharmaceuticals SA, H1 2014
  • Hematological Tumor - Pipeline by ADC Therapeutics Sarl, H1 2014
  • Hematological Tumor - Pipeline by Ability Pharma, SL, H1 2014
  • Hematological Tumor - Pipeline by Pharmedartis GmbH, H1 2014
  • Hematological Tumor - Pipeline by Oncology Venture ApS, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Assessment by Combination Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Hematological Tumor Therapeutics - Recent Pipeline Updates, H1 2014
  • Hematological Tumor - Dormant Projects, H1 2014
  • Hematological Tumor - Dormant Projects (Contd..1), H1 2014
  • Hematological Tumor - Dormant Projects (Contd..2), H1 2014
  • Hematological Tumor - Dormant Projects (Contd..3), H1 2014
  • Hematological Tumor - Discontinued Products, H1 2014

List of Figures

  • Number of Products under Development for Hematological Tumor, H1 2014
  • Number of Products under Development for Hematological Tumor - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Number of Products under Investigation by Universities/Institutes, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Products, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
Back to Top